Literature DB >> 25145553

Controversies in multiple myeloma: to transplant or not?

Isabel Ruth Preeshagul1, Koen Van Besien, Tomer M Mark.   

Abstract

The treatment of multiple myeloma (MM) has dramatically changed in the last decade due to the introduction of the immunomodulatory drugs (IMIDs) and proteasome inhibitors, otherwise known as the novel agents. Prior to the advent of the novel agents, the gold standard of treatment had been high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) for eligible candidates. Given the remarkable activity of the novel agents, and the significant morbidity of HDT/ASCT, the role of stem cell transplantation has now come into question. In this review, we explore the benefits and drawbacks to HDT/ASCT in the era of the novel therapies.

Entities:  

Mesh：

Year:  2014        PMID： 25145553     DOI： 10.1007/s11899-014-0230-5

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  77 in total

1.  Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.

Authors:  Shaji K Kumar; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; Suzanne R Hayman; David Dingli; Francesca Gay; Shirshendu Sinha; Nelson Leung; William Hogan; S Vincent Rajkumar; Morie A Gertz
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

2.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

3.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

4.  Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

Authors:  K Detweiler Short; S V Rajkumar; D Larson; F Buadi; S Hayman; A Dispenzieri; M Gertz; S Kumar; J Mikhael; V Roy; R A Kyle; M Q Lacy
Journal:  Leukemia       Date:  2011-02-25       Impact factor: 11.528

5.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

6.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

7.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Authors:  Ruben Niesvizky; David S Jayabalan; Paul J Christos; Jessica R Furst; Tara Naib; Scott Ely; Jessica Jalbrzikowski; Roger N Pearse; Faiza Zafar; Karen Pekle; April Larow; Richard Lent; Tomer Mark; Hearn J Cho; Tsiporah Shore; Jeffrey Tepler; John Harpel; Michael W Schuster; Susan Mathew; John P Leonard; Madhu Mazumdar; Selina Chen-Kiang; Morton Coleman
Journal:  Blood       Date:  2007-11-07       Impact factor: 22.113

8.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

9.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.

Authors:  Hong Chang; Stephen Sloan; Dan Li; Lihua Zhuang; Qi-Long Yi; Christine I Chen; Donna Reece; Kathy Chun; A Keith Stewart
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

10.  Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

Authors:  Carolina Terragna; Matteo Renzulli; Daniel Remondini; Enrico Tagliafico; Francesco Di Raimondo; Francesca Patriarca; Giovanni Martinelli; Enrica Roncaglia; Luciano Masini; Patrizia Tosi; Elena Zamagni; Paola Tacchetti; Antonio Ledda; Annamaria Brioli; Emanuele Angelucci; Nicoletta Testoni; Giulia Marzocchi; Piero Galieni; Alessandro Gozzetti; Marina Martello; Flores Dico; Katia Mancuso; Michele Cavo
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673
View more
  1 in total

1.  The Association between Cytokines and 365-Day Readmission or Mortality in Adult Cardiac Surgery.

Authors:  Allen D Everett; Shama S Alam; Sherry L Owens; Devin M Parker; Christine Goodrich; Donald S Likosky; Heather Thiessen-Philbrook; Moritz Wyler von Ballmoos; Kevin Lobdell; Todd A MacKenzie; Jeffrey Jacobs; Chirag R Parikh; Anthony W DiScipio; David J Malenka; Jeremiah R Brown
Journal:  J Extra Corpor Technol       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.